{"id":598,"date":"2021-02-26T16:35:04","date_gmt":"2021-02-26T16:35:04","guid":{"rendered":"http:\/\/events.marketsandmarkets.com\/blog\/?p=598"},"modified":"2021-02-26T16:35:04","modified_gmt":"2021-02-26T16:35:04","slug":"discussing-top-10-disruptions-in-biopharma-manufacturing-at-the-marketsandmarkets-biopharma-manufacturing-crystal-ball-event","status":"publish","type":"post","link":"https:\/\/events.marketsandmarkets.com\/blognew\/discussing-top-10-disruptions-in-biopharma-manufacturing-at-the-marketsandmarkets-biopharma-manufacturing-crystal-ball-event\/","title":{"rendered":"Discussing Top 10 Disruptions in BioPharma Manufacturing at the MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT!"},"content":{"rendered":"\n<p><strong>February 26th \u2013 MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT <\/strong>on the <strong>March 11, 2021 <\/strong>will hostindustry giants <strong>Fresenius Kabi, Charles River Laboratories, GenScript ProBio, Pall Corporation and MilliporeSigma<\/strong> to present their thoughts on the Top 10 Disruptions Through BioPharma Manufacturing in the next 5 year!<\/p>\n\n\n\n<p><strong>MarketsandMarkets BioPharma\nManufacturing CRYSTAL BALL EVENT <\/strong>will gather 100+ professionals from industry\ngiants such as <strong><em>Biocon Biologics, Ology Bioservices, Celonic AG, Gyroscope\nTherapeutics, GenIbet, Hemobras, H2i Group, MilliporeSigma, Orange Grove Bio,\nHORIBA, Porex Life Sciences Institute, Kaneka, Lonza, Cytiva, GEA North America,\nBatavia Biosciences, Nova Biomedical, DKSH, GenScript ProBio, Aldevron, Solvias,\nEldon James Corp, Eurofins Genomics, Thermo Fisher Scientific, Syneos Health,\nSYNENTEC, UGA Biopharma, Paras Biopharmaceuticals, GeneSystems, Novasep, Cobra\nBiologics Ltd, Tosoh, OXGENE, Jellagen Ltd, Reading Scientific Services Limited,\netc.<\/em><\/strong><\/p>\n\n\n\n<p>Cell Therapy, Gene Therapy, Monoclonal\nAntibodies, Vaccines, biosimilars and biobetters, plasma therapy, Lab Scale and\nCGMP manufacturing and R&amp;D, Novel downstream bioprocessing methods, Crispr\nand other Gene editing tools and technologies are fuelling The bioproduction\nmarket are expected to grow at over `15% to be a <strong>$305 Bn market in 2025!<\/strong><\/p>\n\n\n\n<p><strong>This event will comprise of 90 minutes of\nbrainstorming among 4 great minds which will aim at bringing out a tangible\naction plan by discussing the question given below:<\/strong><\/p>\n\n\n\n<ul><li>What are the top 10 revenue growth opportunities for\nbioproduction ecosystem participants over the next 5 years? Which markets,\ntechnologies, customer segments ate the most attractive to place bets?<\/li><li>What could be characteristics for an ideal biotech\ninnovator &amp;CROs\/CMOs cooperation for accelerating development and\ncommercialization of cell-based therapeutics?<\/li><li>Which technologies\/approaches are likely to result in the\nimprovement or optimization of production yields, timeline, and supply chain of\nCOVID-19 vaccines?<\/li><li>How can Cell therapy market expand faster in non-oncology\nindications &amp; out of US and how can this transition be expedited?<\/li><li>Will accelerated mRNA vaccine approvals for COVID-19 act\nas being pivotal\/inflection point for the future of RNA Based\/targeted\ntherapeutics?<\/li><li>Single-use systems are thought to increase flexibility\nand reduce production lead times, while lowering capital investment and energy\nrequirements. Can they help cater to increased sophistication in production\nrequirements of personalized or targeted therapeutics?<\/li><\/ul>\n\n\n\n<p><strong>Confirmed Speakers for the event!<\/strong><\/p>\n\n\n\n<ul><li><strong>Rajesh\nDesikan<\/strong>, Vice President &amp; Head, US\nMarketing, Oncology &amp; Immunology Biosimilars, <strong>Fresenius Kabi<\/strong><\/li><li><strong>Dominic\nClarke<\/strong>, Global Head Cell Therapy, Strategy\nand Innovation, <strong>Charles River Laboratories<\/strong><\/li><li><strong>Kenneth Lee<\/strong>, Head of Commercial Division, Americas, <strong>GenScript\nProBio<\/strong><\/li><li><strong>Peter\nLevison<\/strong>, Executive Director &#8211; Business\nDevelopment, <strong>Pall Corporation<\/strong><\/li><li><strong>Ratish\nKrishnan<\/strong>, Associate Director for Cell &amp;\nGene Therapy BioProcessing, <strong>MilliporeSigma<\/strong><\/li><\/ul>\n\n\n\n<p>The\nevent overview, registration details and complete speaker list are available on\nthe official website. The registration for this event is <strong>FREE<\/strong>,\nyou can register for the event <a href=\"https:\/\/events.marketsandmarkets.com\/marketsandmarkets-biopharma-manufacturing-crystal-ball-event\/register\"><strong>HERE<\/strong><\/a>\noryou can directly email on<a href=\"mailto:events@marketsandmarkets.com\">events@marketsandmarkets.com<\/a><strong> <\/strong>asking for more details, your queries and\nprovide feedback.<\/p>\n\n\n\n<p>Markets\nand Markets Conferences (MnM Conferences) produces global summits, congresses\nand conferences bringing together key industry experts from academia and\nindustry, fostering the exchange of ideas and latest research through cutting\nedge conference programs, interactive panel and round table discussions.\nConferences are currently held or planned in the UK, Europe, USA and across\nAsia.<\/p>\n\n\n\n<p>Contact\nPerson \u2013 Shardul Oza\n\nEmail:\n<a href=\"mailto:shardul.oza@marketsandmarkets.com\">shardul.oza@marketsandmarkets.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>February 26th \u2013 MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT on the March 11, 2021 will hostindustry giants Fresenius Kabi, Charles River Laboratories, GenScript ProBio, Pall Corporation and MilliporeSigma to present their thoughts on the Top 10 Disruptions Through BioPharma Manufacturing in the next 5 year! MarketsandMarkets BioPharma Manufacturing CRYSTAL BALL EVENT will gather 100+ professionals [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":601,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_mi_skip_tracking":false},"categories":[3,2,4],"tags":[235,189,126,57,30,106,89,175],"_links":{"self":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/598"}],"collection":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/comments?post=598"}],"version-history":[{"count":2,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/598\/revisions"}],"predecessor-version":[{"id":614,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/posts\/598\/revisions\/614"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media\/601"}],"wp:attachment":[{"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/media?parent=598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/categories?post=598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/events.marketsandmarkets.com\/blognew\/wp-json\/wp\/v2\/tags?post=598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}